Crescent Biopharma, Inc.

NASDAQ:CBIO

Biotechnology

Healthcare
$12.40 -2.69%

-$0.49 today

Market cap
$482.30M
Beta
1.15
P/E (TTM)
-3.3
EPS (TTM)
-$5.33
52W Low $8.72High $27.41

Volume 0.33M

Average 0.28M

CBIO Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Crescent Biopharma, Inc.NASDAQ: CBIO

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $23.28M (cash outflow) rose 893.4% year over year, ahead of the +206.1% change in trailing-twelve-month net income. Sequentially, it fell 74.8% from the prior quarter. Over 3 fiscal years it compounded at +47.5% a year.

Context

  • Net income amounted to 1382.7% of revenue in FY2025.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -$35.26M (-76.5%) for the fiscal year ending Dec 2026, a slowdown from the +295.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$23.28M-74.8% QoQ
Last fiscal yearDec 2025
-$149.94M+295.8% YoY
LTMMar 2026
-$162.08M+206.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+893.4%+31.9%-861.5 pp
1 year+295.8%-76.5%-372.3 pp
3-year CAGR+47.5%-34.0%-81.6 pp
5-year CAGR-24.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(149.94M) USD
Year-over-year change
-295.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +206.1% is the highest of 9, against a peer median of +31.9%.
  • Net income amounts to 1363.9% of revenue for CBIO, versus a peer median of 107.5%.
CBIO Competitors
Net Income for CBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$460M USD+54.4%+9.8%393.2%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$309.06M USD+37.6%+32.1%275948.2%
CBIOCrescent Biopharma, Inc.LTM Mar 2026$162.08M USD+206.1%+47.5%1363.9%
NBPNovaBridge BiosciencesLTM Sep 2025CN¥150.96M CNY-47.8%-67.2%—
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M USD+26.1%-14.6%44.8%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$68.17M USD+23.5%+19.2%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$59.14M USD-242.2%-44.1%166.4%
ZYMEZymeworks Inc.LTM Sep 2026$43.31M USD+168.3%—16.3%
CNTXContext Therapeutics Inc.LTM Mar 2026$40.23M USD+45.6%+34.5%—
CGENCompugen Ltd.LTM Dec 2025$35.34M USD——48.6%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CBIO) —+31.9%+9.8%107.5%

Competitors are the stored peer set for CBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(63.43M)(46.69M)(36.9M)(37.88M)(149.94M)
Depreciation & Amortization264.6K207.15K153.3K35.17K84K
Deferred Income Tax2.17K0000
Stock-Based Compensation6.09M3.86M3.56M4.77M13.3M
Change in Working Capital(1.17M)(4.66M)(2.56M)1.16M(13.37M)
Accounts Receivables0000(18M)
Inventory00000
Accounts Payables17.68K(1.14M)(102.08K)(538.81K)2.08M
Other Working Capital(1.18M)(3.52M)(2.46M)1.7M2.55M
Other Non-Cash Items749.04K828.51K864.87K814.48K78.4M
Operating Cash Flow(57.49M)(46.46M)(34.88M)(31.1M)(71.53M)
Capital Expenditures(14.94K)(84.19K)(21.39K)(9.97K)(919K)
Acquisitions (Net)00030K0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0000(72M)
Investing Cash Flow(14.94K)(84.19K)(21.39K)20.03K(72.92M)
Debt Repayment00000
Common Stock Issued10.7M4.16M28.71M5.4K5K
Common Stock Repurchased0000(177K)
Dividends Paid00000
Other Financing Activities25.03K0116.5K0323.16M
Financing Cash Flow10.72M4.16M28.82M5.4K322.98M
Effect of Forex Changes00000
Net Change in Cash(46.78M)(42.38M)(6.08M)(31.07M)178.53M
Free Cash Flow(57.5M)(46.54M)(34.9M)(31.11M)(72.45M)

Crescent Biopharma, Inc.

NASDAQ:CBIO

Intrinsic Alpha fair value

Locked

Current Price

$12.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.